COMP <GO>
TNDM vs NVCR // RSI-14 & 200D SMA MOMENTUM
Tandem Diabetes Care Inc. (NASDAQ) VS. NovoCure Limited (NASDAQ) • 15-METRIC TALLY: TNDM 4
— NVCR 6
▲ RSI-14 & 200D SMA MOMENTUM LEADER: TNDM
LAST: $19.79 (+0.56%) • MKT CAP: $1.38B
rsi-technicals
62.4
LAST: $13.11 (-7.48%) • MKT CAP: $1.53B
rsi-technicals
34.0
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (TNDM VS. NVCR)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | TNDM | NVCR | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 53.80% | 74.50% | -20.70 | NVCR | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | -27.50% | -7.50 | NVCR | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -2.15% | -4.96% | +2.81 | TNDM | /fcf-yield <GO> |
| Operating Margin | -18.50% | -23.50% | +5.00 | TNDM | /operating-margins <GO> |
| Net Profit Margin | -20.20% | -20.80% | +0.60 | TNDM | /net-margins <GO> |
| Revenue Growth (YoY) | 7.90% | 8.30% | -0.40 | NVCR | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 0.20 | 0.54 | -0.34 | NVCR | /balance-sheet <GO> |
| Piotroski F-Score Quality | 4/9 | 6/9 | -2.00 | NVCR | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum ACTIVE | 62.4 | 34.0 | +28.31 | TNDM | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $1.38B | $1.53B | -$149.6M | NVCR | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | TNDM REV | NVCR REV | TNDM GROSS % | NVCR GROSS % | TNDM FCF | NVCR FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $1.01B | $655.4M | 53.8% | 74.5% | -$29.7M | -$75.7M |
| FY 2024 | $940.2M | $605.2M | 52.1% | 77.3% | $5.0M | -$69.2M |
| FY 2023 | $747.7M | $509.3M | — | — | -$31.8M | -$73.3M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
TNDM // BETA —
NVCR // BETA —